Experience and Education
Ankara University Faculty of Medicine
Internal Medicine Residency: Süleyman Demirel University Faculty of Medicine Hospital, Department of Internal Medicine
Medical Oncology Specialty: Hacettepe University Faculty of Medicine, Oncology Hospital, Medical Oncology Department
Research Interests
Breast cancer
Genitourinary cancers
Gastrointestinal (stomach, intestine, pancreas) cancers
Brain tumors
| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
|---|---|---|---|---|---|---|---|---|
| CLINICAL TRIAL | IZMIR MPH | ABBVIE TIBBI ILACLAR SAN. VE TIC. LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT04928846 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer | ONGOING | https://clinicaltrials.gov/study/NCT03362177 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | ONGOING | https://clinicaltrials.gov/study/NCT03937154 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy | ONGOING | https://clinicaltrials.gov/study/NCT05740566 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) | ONGOING | https://clinicaltrials.gov/study/NCT05920356 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy | ONGOING | https://clinicaltrials.gov/study/NCT06117774 |
| CLINICAL TRIAL | IZMIR MPH | AMGEN ILAC TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy | ONGOING | https://clinicaltrials.gov/study/NCT06691984 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy | ONGOING | https://clinicaltrials.gov/study/NCT05221840 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study) | ONGOING | https://clinicaltrials.gov/study/NCT03732820 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer. | ONGOING | https://clinicaltrials.gov/study/NCT03732677 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) | ONGOING | https://clinicaltrials.gov/study/NCT04784715 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1) | ONGOING | https://clinicaltrials.gov/study/NCT04884360 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency. | ONGOING | https://clinicaltrials.gov/study/NCT04493853 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA) | ONGOING | https://clinicaltrials.gov/study/NCT05043090 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) | ONGOING | https://clinicaltrials.gov/study/NCT04550260 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02) | ONGOING | https://clinicaltrials.gov/study/NCT05374512 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) | ONGOING | https://clinicaltrials.gov/study/NCT04960709 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study | ONGOING | https://clinicaltrials.gov/study/NCT04964934 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours | ONGOING | https://clinicaltrials.gov/study/NCT05489211 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. | ONGOING | https://clinicaltrials.gov/study/NCT04931654 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) | ONGOING | https://clinicaltrials.gov/study/NCT06120491 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) | ONGOING | https://clinicaltrials.gov/study/NCT04862663 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | ONGOING | https://clinicaltrials.gov/study/NCT05348577 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence | ONGOING | https://clinicaltrials.gov/study/NCT05774951 |
| CLINICAL TRIAL | IZMIR MPH | ASTRAZENECA ILAC SAN.VE TIC.LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) | ONGOING | https://clinicaltrials.gov/study/NCT06129864 |
| CLINICAL TRIAL | IZMIR MPH | BAYER CONSUMER AG | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | Missing | A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH | ONGOING | https://clinicaltrials.gov/study/NCT04597125 |
| CLINICAL TRIAL | IZMIR MPH | BEIGENE | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | ONGOING | https://clinicaltrials.gov/study/NCT05909904 |
| CLINICAL TRIAL | IZMIR MPH | BIONTECH | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT06449209 |
| CLINICAL TRIAL | IZMIR MPH | BIONTECH | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer | ONGOING | https://clinicaltrials.gov/study/NCT06449222 |
| CLINICAL TRIAL | IZMIR MPH | BIONTECH | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 / PHASE 3 | A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT06712316 |
| CLINICAL TRIAL | IZMIR MPH | BIONTECH | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT06712355 |
| CLINICAL TRIAL | IZMIR MPH | GILEAD SCİENCES-PRAHS | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer | ONGOING | https://clinicaltrials.gov/study/NCT04527991 |
| CLINICAL TRIAL | IZMIR MPH | GILEAD SCİENCES-PRAHS | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 | ONGOING | https://clinicaltrials.gov/study/NCT05382286 |
| CLINICAL TRIAL | IZMIR MPH | GILEAD SCİENCES-PRAHS | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 | ONGOING | https://clinicaltrials.gov/study/NCT05382299 |
| CLINICAL TRIAL | IZMIR MPH | GILEAD SCİENCES-PRAHS | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer | ONGOING | https://clinicaltrials.gov/study/NCT03547973 |
| CLINICAL TRIAL | IZMIR MPH | ICON ANKARA KLINIK ARASTIRMA DIS. TIC. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 / PHASE 3 | A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | ONGOING | https://clinicaltrials.gov/study/NCT04613596 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 | ONGOING | https://clinicaltrials.gov/study/NCT03523585 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) | ONGOING | https://clinicaltrials.gov/study/NCT04205812 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | Missing | A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy | ONGOING | https://clinicaltrials.gov/study/NCT05874401 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | ONGOING | https://clinicaltrials.gov/study/NCT05678673 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) | ONGOING | https://clinicaltrials.gov/study/NCT06018337 |
| CLINICAL TRIAL | IZMIR MPH | IQVIA TIBBI ISTATISTIK LTD.STI | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | ONGOING | https://clinicaltrials.gov/study/NCT06635824 |
| CLINICAL TRIAL | IZMIR MPH | JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy | ONGOING | https://clinicaltrials.gov/study/NCT02531516 |
| CLINICAL TRIAL | IZMIR MPH | JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | ONGOING | https://clinicaltrials.gov/study/NCT03748641 |
| CLINICAL TRIAL | IZMIR MPH | JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | Missing | Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | ONGOING | https://clinicaltrials.gov/study/NCT04640623 |
| CLINICAL TRIAL | IZMIR MPH | LILLY ILAC TICARET LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT04194944 |
| CLINICAL TRIAL | IZMIR MPH | LILLY ILAC TICARET LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | ONGOING | https://clinicaltrials.gov/study/NCT03155997 |
| CLINICAL TRIAL | IZMIR MPH | LILLY ILAC TICARET LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC | ONGOING | https://clinicaltrials.gov/study/NCT04819100 |
| CLINICAL TRIAL | IZMIR MPH | LILLY ILAC TICARET LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer | ONGOING | https://clinicaltrials.gov/study/NCT05288166 |
| CLINICAL TRIAL | IZMIR MPH | LILLY ILAC TICARET LTD.STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence | ONGOING | https://clinicaltrials.gov/study/NCT05514054 |
| CLINICAL TRIAL | IZMIR MPH | MEDPACE | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 / PHASE 3 | A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | ONGOING | https://clinicaltrials.gov/study/NCT06225596 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03) | ONGOING | https://clinicaltrials.gov/study/NCT05609968 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC | ONGOING | https://clinicaltrials.gov/study/NCT05298423 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) | ONGOING | https://clinicaltrials.gov/study/NCT03036488 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) | ONGOING | https://clinicaltrials.gov/study/NCT03924869 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | ONGOING | https://clinicaltrials.gov/study/NCT02861573 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | ONGOING | https://clinicaltrials.gov/study/NCT04634877 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008) | ONGOING | https://clinicaltrials.gov/study/NCT05224141 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | ONGOING | https://clinicaltrials.gov/study/NCT03486873 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT05722015 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) | ONGOING | https://www.clinicaltrials.gov/study/NCT04895358 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010) | ONGOING | https://clinicaltrials.gov/study/NCT05665595 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B | ONGOING | https://clinicaltrials.gov/study/NCT05319730 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001) | ONGOING | https://clinicaltrials.gov/study/NCT05933577 |
| CLINICAL TRIAL | IZMIR MPH | MERCK SHARP DOHME ILACLARI LTD. STI. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors | ONGOING | https://clinicaltrials.gov/study/NCT06305754 |
| CLINICAL TRIAL | IZMIR MPH | NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | ONGOING | https://clinicaltrials.gov/study/NCT05827081 |
| CLINICAL TRIAL | IZMIR MPH | PAREXEL INTERNATIONAL(IRL)LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) | ONGOING | https://clinicaltrials.gov/study/NCT05061550 |
| CLINICAL TRIAL | IZMIR MPH | PAREXEL INTERNATIONAL(IRL)LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy | ONGOING | https://clinicaltrials.gov/study/NCT06095583 |
| CLINICAL TRIAL | IZMIR MPH | PAREXEL INTERNATIONAL(IRL)LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma | ONGOING | https://www.clinicaltrials.gov/study/NCT06054555 |
| CLINICAL TRIAL | IZMIR MPH | PAREXEL INTERNATIONAL(IRL)LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study | ONGOING | https://clinicaltrials.gov/study/NCT06492616 |
| CLINICAL TRIAL | IZMIR MPH | PFIZER | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2) | ONGOING | https://clinicaltrials.gov/study/NCT05654623 |
| CLINICAL TRIAL | IZMIR MPH | PPD GLOBAL LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer | ONGOING | https://clinicaltrials.gov/study/NCT04961996 |
| CLINICAL TRIAL | IZMIR MPH | REGENERON | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% | ONGOING | https://clinicaltrials.gov/study/NCT05557591 |
| CLINICAL TRIAL | IZMIR MPH | REGENERON | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 / PHASE 3 | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% | ONGOING | https://www.clinicaltrials.gov/study/NCT05785767 |
| CLINICAL TRIAL | IZMIR MPH | ROCHE MUSTAHZARLARI SAN. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy | ONGOING | https://clinicaltrials.gov/study/NCT04660344 |
| CLINICAL TRIAL | IZMIR MPH | ROCHE MUSTAHZARLARI SAN. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ONGOING | https://www.clinicaltrials.gov/study/NCT05775289 |
| CLINICAL TRIAL | IZMIR MPH | ROCHE MUSTAHZARLARI SAN. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 | A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy | ONGOING | https://clinicaltrials.gov/study/NCT05645692 |
| CLINICAL TRIAL | IZMIR MPH | ROCHE MUSTAHZARLARI SAN. A.S. | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | ONGOING | https://clinicaltrials.gov/study/NCT05904886 |
| CLINICAL TRIAL | IZMIR MPH | SYNEOS HEALTH UK LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 2 / PHASE 3 | An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 | ONGOING | https://clinicaltrials.gov/study/NCT04534205 |
| CLINICAL TRIAL | IZMIR MPH | SYNEOS HEALTH UK LIMITED | MEDICAL ONCOLOGY | PROF DR CAGATAY ARSLAN | PHASE 3 | A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | ONGOING | https://clinicaltrials.gov/study/NCT06643117 |
| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
| Location | Branch | Firm | Phase | Official Title | https://clinicaltrials.gov/ |
|---|---|---|---|---|---|
| Izmir MPH | Medical Oncology | GSK | Phase 2/3 | A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung) | https://clinicaltrials.gov/study/NCT04655976 |
| Izmir MPH | Medical Oncology | Icon Ankara Klinik Araştırma Dış. Tic. A.Ş. | Phase 3 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | https://clinicaltrials.gov/study/NCT03349710 |
| Izmir MPH | Medical Oncology | Johnson and Johnson Sıhhi Malz. San. ve Tic. Ltd. Şti. | Phase 3 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | https://clinicaltrials.gov/study/NCT02489318 |
| Izmir MPH | Medical Oncology | Johnson and Johnson Sıhhi Malz. San. ve Tic. Ltd. Şti. | Phase 3 | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | https://clinicaltrials.gov/study/NCT04487080 |
| Izmir MPH | Medical Oncology | Johnson and Johnson Sıhhi Malz. San. ve Tic. Ltd. Şti. | Phase 3 | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | https://clinicaltrials.gov/study/NCT04538664 |
| Izmir MPH | Medical Oncology | Johnson and Johnson Sıhhi Malz. San. ve Tic. Ltd. Şti. | Phase 3 | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure | https://clinicaltrials.gov/study/NCT04988295 |
| Izmir MPH | Medical Oncology | Johnson and Johnson Sıhhi Malz. San. ve Tic. Ltd. Şti. | Phase 3 | A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy | https://clinicaltrials.gov/study/NCT05388669 |
| Izmir MPH | Medical Oncology | Lilly İlaç Ticaret Ltd.Şti. | Phase 2 | An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT03703466 |
| Izmir MPH | Medical Oncology | Lilly İlaç Ticaret Ltd.Şti. | Phase 3 | postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy | https://clinicaltrials.gov/study/NCT05169567 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) | https://clinicaltrials.gov/study/NCT02819518 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma | https://clinicaltrials.gov/study/NCT02853305 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) | https://clinicaltrials.gov/study/NCT03189719 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598) | https://clinicaltrials.gov/study/NCT03302234 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604) | https://clinicaltrials.gov/study/NCT03066778 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma | https://clinicaltrials.gov/study/NCT04003636 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010). | https://clinicaltrials.gov/study/NCT04199104 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 3 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) | https://clinicaltrials.gov/study/NCT04246177 |
| Izmir MPH | Medical Oncology | Merck Sharp Dohme İlaçları Ltd. Şti. | Phase 2 | A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A. | https://clinicaltrials.gov/study/NCT05342636 |
| Izmir MPH | Medical Oncology | Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. | Phase 3 | A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment | https://clinicaltrials.gov/study/NCT02422615 |
| Izmir MPH | Medical Oncology | Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. | Phase 3 | A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC) | https://clinicaltrials.gov/study/NCT03447769 |
| Izmir MPH | Medical Oncology | Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. | Phase 2 | A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N) | https://clinicaltrials.gov/study/NCT03968419 |
| Izmir MPH | Medical Oncology | Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. | Phase 2 | KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | https://clinicaltrials.gov/study/NCT05445843 |
| Izmir MPH | Medical Oncology | Parexel International (IRL) Limited | Phase 3b | A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations. | https://clinicaltrials.gov/study/NCT03286842 |
| Izmir MPH | Medical Oncology | Parexel International (IRL) Limited | Phase 3 | A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | https://clinicaltrials.gov/study/NCT04063163 |
| Izmir MPH | Medical Oncology | Parexel International (IRL) Limited | Phase 3 | A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | https://clinicaltrials.gov/study/NCT04248829 |
| Izmir MPH | Medical Oncology | PPD Global Limited | Phase 2 | Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen | https://clinicaltrials.gov/study/NCT04549025 |
| Izmir MPH | Medical Oncology | PPD Global Limited | Phase 2 | A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients | https://clinicaltrials.gov/study/NCT03785925 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection | https://clinicaltrials.gov/study/NCT02450331 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 2 | A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy | https://clinicaltrials.gov/study/NCT03498521 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 2 | An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT03386721 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 2/3 | A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial) | https://clinicaltrials.gov/study/NCT03178552 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | https://clinicaltrials.gov/study/NCT02807636 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | https://clinicaltrials.gov/study/NCT03452137 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | https://clinicaltrials.gov/study/NCT04256421 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer | https://clinicaltrials.gov/study/NCT03498716 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab. | https://clinicaltrials.gov/study/NCT05091567 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer | https://clinicaltrials.gov/study/NCT04222972 |
| Izmir MPH | Medical Oncology | Roche Müstahzarları San. A.Ş. | Phase 3 | A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | https://clinicaltrials.gov/study/NCT06267001 |
| Izmir MPH | Medical Oncology | Sanofi | Phase 3 | Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors | https://clinicaltrials.gov/study/NCT04154956 |
| Izmir MPH | Medical Oncology | Sanofi | Phase 2 | Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT04659603 |
| Izmir MPH | Medical Oncology | Sanofi | Phase 3 | A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | https://clinicaltrials.gov/study/NCT04478266 |
| Izmir MPH | Medical Oncology | Syneos Health UK Limited | Phase 3 | A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer. | https://clinicaltrials.gov/study/NCT04100018 |
| Location | Branch | Firm | Phase | Official Title | https://clinicaltrials.gov/ |